Abstract
Twenty-six patients with metastatic breast cancer were offered a phase II combination of recombinant α-interferon and continuous-infusion 5-fluorouracil (5-FU). 5-FU was administered at 750 mg/m2daily for 5 days as a continuous infusion and recombinant interferon at 5 million U/m2subcutaneously days 1, 3, and 5 of each course. The courses were repeated every 14 days. Despite moderate nonmyelosuppressive toxicity, only two (8%) partial remissions were observed. In this schedule, the addition of recombinant α-interferon to conventional continuous-infusion 5-FU resulted in a response rate of 8%.
Original language | English (US) |
---|---|
Pages (from-to) | 185-187 |
Number of pages | 3 |
Journal | Journal of Immunotherapy |
Volume | 18 |
Issue number | 3 |
DOIs | |
State | Published - Oct 1995 |
Keywords
- 5-Fluorouracil
- Interferon
- Metastatic breast cancer
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pharmacology
- Cancer Research